- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00803933
Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
Phase II b Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
Human African Trypanosomiasis or sleeping sickness has made a spectacular return during the last decade, and in many places the demand largely surpasses the capacities of the treatment centers. Treatment of the disease remains unsatisfactory. All currently used drugs must be administered parenterally, treatment is lengthy, and adverse drug reactions frequent. There are currently no drugs that are easily administered and have low toxicity, and might thus be used as tools to support disease control.
This study aims to compare the safety and efficacy of DB289, a new, orally administered dication prodrug to pentamidine i.m. injection for the treatment of first stage sleeping sickness. The project will be executed in the framework of an international consortium consisting of several partners from academia, industry and from the Democratic Republic of Congo Ministries of Health.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Kinshasa
-
Gombe, Kinshasa, Congo
- CDTC Maluku
-
Gombe, Kinshasa, Congo
- Vanga Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient has early stage T. b. gambiense infection i.e. parasitologically confirmed infection in the blood or lymph node aspirate and greater than or equal to 5 WBC mm-3 detected in the CSF by microscopic examination
- Patient is 15 to 50 years old
- Patient has a minimal weight of 35 kilograms
If the patient is female of child bearing potential (a women will be considered of non-child bearing potential only if she has been post menopausal for over 2 years or has had a hysterectomy):
- she is not lactating,
- she had a negative urine pregnancy test result within 24 hours prior to DB289 treatment and
- she agrees to use a medically proven method of contraception (abstinence from sexual intercourse is an acceptable method) from the day of consent on until the end of the observation period (day 7).
- Patient has understood and signed the Informed Consent. If the patient is minor, a legal guardian has signed the Informed Consent
Exclusion Criteria:
- The patient has late stage T.b. gambiense infection i.e. presence of parasite in the CSF upon microscopic examination or a WBC count of > 5mm-1
- Active clinically relevant medical conditions that in the Investigator opinion may jeopardize subject safety or interfere with participation in the study, including but not limited to: significant liver diseases, chronic pulmonary diseases, significant cardiovascular diseases, diabetes, thyroid diseases, gout, infection including known HIV infection, CNS trauma or seizure disorders (A list of typical signs and symptoms is provided for guidance of the investigator in attachment 1)
- Coma Score of less than 9 on the Glasgow Coma Scale (Appendix 8)
- Withdrawal of consent at any time during the study
- Any condition which compromises ability to communicate with the investigator as required for the completion of this study.
- The subject has been previously treated for African Trypanosomiasis.
- The subject has been previously enrolled in the study. -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DB289
Pafuramidine maleate (DB289), 100 mg BID orally
|
Pafuramidine maleate (DB289), 100 mg BID orally
Other Names:
|
Active Comparator: Pentamidine
Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM
|
Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary efficacy endpoint was the parasitological cure at 3 months after completion of treatment.
Time Frame: 3 months
|
3 months
|
The primary outcome measure for safety analysis was the rate of occurrence of Grade 3 or higher adverse events during the observation period.
Time Frame: 12 day
|
12 day
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The secondary outcome measure was the incidence rate of adverse events (all Grades combined) during the 7- to 9-day observation period in Treatment Sequence 1 and during the 12-day observation period in Treatment Sequence 2.
Time Frame: 12 day
|
12 day
|
The number and percentage of subjects with parasitological cure, subjects with confirmed (parasitological) treatment failure, and subjects with suspected treatment failure at 6, 12, and 24 months after completion of treatment.
Time Frame: 6, 12, 24 months
|
6, 12, 24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Victor Kande, MD, Programme Nationale de Lutte contre la trypanosomiase humaine Africaine
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 289-C-006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on African Trypanosomiasis
-
Drugs for Neglected DiseasesInstitute of Tropical Medicine, Belgium; Institut National de Recherche Biomédicale... and other collaboratorsNot yet recruitingHuman African Trypanosomiasis
-
Drugs for Neglected DiseasesSanofiCompletedHuman African TrypanosomiasisFrance
-
Institut de Recherche pour le DeveloppementInstitute of Tropical Medicine, Belgium; Institut National de Recherche Biomédicale... and other collaboratorsCompletedTrypanosoma Brucei Gambiense; Infection | Sleeping Sickness; West African | African Trypanosomiases | West African; TrypanosomiasisCongo, The Democratic Republic of the, Côte D'Ivoire, Guinea
-
Drugs for Neglected DiseasesCompletedHuman African Trypanosomiasis (HAT)Congo, The Democratic Republic of the
-
Institut de Recherche pour le DeveloppementInstitute of Tropical Medicine, Belgium; Institut National de Recherche Biomédicale... and other collaboratorsCompletedSleeping Sickness | Human African Trypanosomiasis | Trypanosoma Brucei Gambiense; Infection | African Trypanosomiases | West African Sleeping Sickness | Trypanosomiasis; African, Due to Trypanosoma Brucei Gambiense, GambienseCongo, The Democratic Republic of the, Côte D'Ivoire, Burkina Faso
-
Institute of Tropical Medicine, BelgiumCompletedHuman African TrypanosomiasisCongo, The Democratic Republic of the
-
Drugs for Neglected DiseasesCompletedHuman African Trypanosomiasis (HAT)Congo, The Democratic Republic of the
-
Drugs for Neglected DiseasesCompletedSleeping Sickness | Human African Trypanosomiasis (HAT)Central African Republic, Congo, The Democratic Republic of the, Congo
-
Drugs for Neglected DiseasesSwiss Tropical & Public Health Institute; Ministry of Public Health, Democratic...Completed
-
Institut de Recherche pour le DeveloppementFoundation for Innovative New Diagnostics; Programme National de lutte contre... and other collaboratorsCompletedSleeping Sickness | Human African Trypanosomiasis | Trypanosoma Brucei Gambiense; Infection | West African Sleeping SicknessCôte D'Ivoire, Guinea
Clinical Trials on DB289
-
Immtech Pharmaceuticals, IncCompletedProphylactic Activity Against MalariaUnited States
-
Immtech Pharmaceuticals, IncBill and Melinda Gates FoundationCompletedTrypanosomiasis, AfricanAngola, Congo
-
Immtech Pharmaceuticals, IncTerminatedHIV Infections | Pneumonia, Pneumocystis Carinii | Pneumocystis Carinii Pneumonia | Pneumonia, Interstitial Plasma CellUnited States